All entries for: Alnylam Pharmaceuticals, Inc.

February 12, 2026

Alnylam Pharmaceuticals, Inc.

Neutral Outlook

Cambridge, MA
1,001-5,000 employees

Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties or a potential excise tax. The impact of the IRA on the pharmaceutical industry is significant and ongoing.

Disease Area: Cardiology, Metabolic Diseases, Neurological Diseases, Rare Disease
Drug Type: Biologic
Scroll to Top